Introduction
Coxsackieviruses B1-B6 (CVB), members of the enterovirus group in the family Picornaviridae, are non-enveloped viruses with single-stranded plus-sense RNA contained in a capsid composed of 60 protomers, each consisting of one copy of the viral proteins VP1, VP2, VP3 and VP4 (Rueckert, 1996) . A common receptor for CVB and adenoviruses, called CAR, has been identified (Bergelson et al., 1997 ; Tomko et al., 1997) .
CVB are highly prevalent human pathogens associated with a variety of acute diseases (myocarditis, meningoencephalitis, Bornholm disease, herpangina …) (Melnick, 1996) . Studies have indicated that CVB3 and CVB4 may have a causal role in chronic diseases such as chronic myocarditis and insulin-dependent type 1 diabetes (Kandolf et al., 1993 ; Graves et al., 1997) .
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Fax j33 3 20 44 52 81. e-mail dhober!chru-lille.fr Primary replication of enteroviruses takes place in tissues of the respiratory and gastrointestinal tracts. This may be followed by the occurrence of infectious virus in blood which leads to spread to secondary target organs (Melnick, 1996) . A viraemia is often detected in hospitalized patients with enterovirus diseases (Prather et al., 1984) . Increased levels of IFN-α in plasma have been associated with CVB infection, and IFN-α mRNA has been detected in the blood cells of individuals with enterovirus RNA, with high identity to CVB3 and CVB4 in most cases, in their blood (Dommergues et al., 1994 ; .
A variety of viruses and virally infected cells are capable of inducing IFN-α production by human peripheral blood mononuclear cells (PBMCs) in short-term in vitro culture studies. Coxsackieviruses are frequently referred to as ' weak ' IFN-α inducers compared with ' strong ' IFN-α inducers like Sendai virus (SV) and herpes simplex virus type 1 (HSV-1) (Pitkaranta et al., 1988 ; Pitkaranta & Hovi, 1993 ; Feldman et al., 1994) . In response to SV, the predominant IFN-α-producing cells have been reported to be monocytes (Saksela et al., 1984 ; Gobl et al., 1988) , whereas in response to HSV-1, dendritic cell precursors produce IFN-α (Siegal et al., 1999) . The mechanisms of CVBinduced synthesis of IFN-α have not been elucidated.
Infectious CVB4 and\or its components can be found in circulating blood of patients and consequently they may induce synthesis of IFN-α by IFN-α-producing blood cells. Recently, it has been reported that human polyvalent IgG enhances the in vitro IFN-α-inducing capacity of poliovirus, a member of the enterovirus group (Palmer et al., 2000) . Humans are frequently exposed to sequential CVB challenges ; therefore serotype and CVB group-specific antibodies can be found in the circulating blood of individuals meeting subsequent CVB infection (Frisk et al., 1989 ; Gauntt, 1997) . In this study, the role of antibodies isolated from plasma of CVB4-seropositive subjects in the IFN-α-response of PBMCs to CVB4 has been investigated in vitro.
Methods
Viruses. CVB4 (JBV strain, provided by J. W. Almond, Aventis Pasteur, Marcy-L'Etoile, France) were grown in Hep-2 cells (BioWhittaker) in Eagle's MEM (Gibco BRL) supplemented with 10 % heatinactivated foetal calf serum (Gibco BRL) and 1 % -glutamine (Eurobio). Supernatants were collected 3 days post-infection and then clarified at 1000 r.p.m. for 10 min. Virus titres were determined by plaque formation assay on Hep-2 cells and aliquots of virus preparations were then stored frozen at k80 mC.
SV was provided by D. Garcin (Department of Genetics and Microbiology, University of Geneva, Switzerland). The virus was cultivated as previously described (Garcin et al., 1995) . Briefly, SV was propagated in eggs and purified by first clarifying chorioallantoic fluid containing SV by centrifugation for 10 min at 1500 g at 4 mC, and then pelleting the SV at 15 000 g for 16 h. Virus titres were assayed by plaque formation on HeLa cells, and the virus preparation was stored frozen at k80 mC until use.
HSV (laboratory strain) was cultivated in a Vero cell line (ATCC) in MEM supplemented with 5 % FCS and 1 % -glutamine. After 48 h incubation at 37 mC in an atmosphere of 5 % humidified CO # , supernatants were collected and clarified at 1000 r.p.m. for 10 min. HSV-1 titres were assayed by plaque formation on Vero cells and virus preparations were stored at k80 mC.
Blood donors. Blood samples were obtained from 20 healthy subjects with anti-coxsackievirus B antibodies detected by neutralization assay in their blood (titre 1\2 to 1\32) : 10 adults (6 males and 4 females ; median age 28 years, range 23-45) and 10 children (5 males and 5 females ; median age 12 years, range 7-16), who had no suspected immunological, infectious or metabolic disease.
Blood samples were also obtained from 6 children (4 males and 2 females ; median age 6 months, range 6-12) with negative detection of anti-CVB antibodies by neutralization assay.
IFN-α induction. Venous blood was collected in sterile 7n5 ml tubes (Becton Dickinson) containing 20 IU\ml heparin (Heparin Choay, Sanofi). PBMCs were separated over a Ficoll-paque solution (Diatrizoate Ficoll, Eurobio) (Boyum, 1976) . The mononuclear cells were collected, washed three times with RPMI 1640, adjusted to a concentration of 2i10' cells\ml in RPMI supplemented with 10 % FCS and 1 % -glutamine, and then distributed as 0n1 ml aliquots into 96-well tissue culture plates.
Thereafter, 0n1 ml of medium containing virus at an m.o.i. of 1 or medium containing virus at a m.o.i. of 1 and plasma or various preparations obtained by using affinity chromatography of plasma was added to wells, followed by incubation for 48 h at 37 mC in a 5% CO # atmosphere. Then, culture supernatant was harvested, cleared of cells by centrifugation for 10 min at 1000 r.p.m., and stored at k20 mC until assayed for the presence of IFN-α. Cultures not treated with viruses served as controls.
Cell separation.
(1) A monocyte isolation technique based on Optiprep density-gradient medium was described previously (GrazianiBowering et al., 1997) . Briefly, PBMCs were isolated from whole blood as described above. Four ml of Optiprep (Sigma) was mixed with 10 ml of PBMCs before overlaying with 7n5 ml of a 1n078 g\ml lymphocytespecific density layer. The latter was overlaid with 20 ml of 1n068 g\ml solution and 0n5 ml of HEPES-buffered saline (Sigma). Centrifugation was carried out at 600 g for 25 min at room temperature. Fractions of the resulting phases were collected. The first fraction corresponded to monocytic cells at the 1n068 g\ml layer ; a second fraction included the lymphocyte-trapping layer at the interface of the 1n078 g\ml and 1n068 g\ml layers. Each fraction was washed once with PBS and twice with RPMI 1640, adjusted to a concentration of 2i10' cells\ml in RPMI supplemented with 10 % FCS and 1 % -glutamine, and then distributed as 0n1 ml aliquots into 96-well tissue culture plates. The cells at the 1n068 g\ml layer were 90-95 % CD14 + monocytes as determined using FITC monoclonal anti-CD14 conjugated antibody (data not shown).
(2) PBMCs were isolated from whole blood as described above, and washed with PBS (E. Merck)k2 % FCS. Specific immunomagnetic beads (Dynal Dynabeads M-450 CD14) were used for depletion of CD14 + cells from PBMCs, according to the manufacturer's instructions. 20i10' PBMC\ml were incubated with 20i10' beads\ml for 60 min at 4 mC. The proportion of CD14 + cells in the CD14-negative population was 5 %. CD14-positive and -negative populations were washed and resuspended at 2i10' cells\ml in RPMI supplemented with 10 % FCS and 1 % -glutamine.
Immunoassay for IFN-α. The concentration of IFN-α was determined by a specific and sensitive dissociation-enhanced lanthanide fluoroimmunoassay (DELFIA) based on the direct sandwich technique using a mixture of two murine monoclonal antibodies (MAbs) to human IFN-α, LT27 : 273 and LT27 : 293, which bind more than 90 % of natural IFN-α subtypes coated onto microtitre plate wells (LKB Wallac), and a europium-labelled murine anti-human IFN-α, as previously described (Cederblad et al., 1998) . Samples (100 µl) diluted with an equal volume of dilution buffer containing an irrelevant IgG1 mouse monoclonal (B1 : 2) at 50 µg\ml were then added to the plate. After 2 h, plates were washed three times, and 0n2 ml of the europium-conjugated antibody at 1\800 dilution was added per well in dilution buffer. After 1 h, the plates were washed six times and 0n2 ml of Enhancement solution (LKB Wallac) was added per well to promote dissociation of Eu$ + cations from the labelled antibody into solution, where they form fluorescent chelates with components of the Enhancement solution. After 20 min, the fluorescence in the wells was measured in a time-resolved fluorimeter (1230 Arcus fluorimeter, LKB Wallac). The National Institutes of Health leukocyte reference interferon G-23-902-530 was used as standard.
Affinity chromatography.
(1) Protein A-Sepharose CL-4B. Plasma samples (2 ml) collected from five healthy subjects were diluted twofold with PBS at pH 7n0, filtered (0n45 µm) and passed at flow rate of 0n1 ml\min over a 1n6 cmi20 cm column of Protein A-Sepharose CL-4B (Pharmacia), equilibrated with PBS buffer. The column was then washed extensively with the same buffer until the A #)! of the effluent was zero, and eluted at a flow rate of 1 ml\min with elution buffer containing 50 mM glycine (Sigma) and 150 mM NaCl (E. Merck), pH 3n0. Fractions BJAA CVB4-antibody complexes induce IFN-α production CVB4-antibody complexes induce IFN-α production containing the eluted immunoglobulins were pooled and concentrated on a Biomax-30 membrane in the Centricon Plus-20 system (Millipore). To preserve the activity of acid-labile IgG, the eluted fractions were neutralized by adding 50-100 µl of 1 M Tris-HCl, pH 9 (Sigma). IgG concentrations were estimated using an assumed extinction coefficient of 1n43 for a 1 mg\ml solution at 280 nm.
(2) CVB4-Sepharose CL-4B. Sepharose CL-4B was activated with divinylsulfone (DVS ; Sigma) as described previously (Lihme et al., 1986) . 2i10"! p.f.u.\ml CVB4 obtained by ultracentrifugation for 1 h at 50 0000 g were resuspended in 25n5 g\l NaHCO $ (40 ml) (E. Merck) and mixed with DVS-activated Sepharose CL-4B (20 ml) which had been washed with NaHCO $ . After gentle mixing for 16 h at room temperature, the free reaction sites were saturated by incubation for 3 h with glycine buffer, pH 9n0, containing 80n5 g\l glycine and 25n5 g\l NaHCO $ . The slurry was then washed five times with distilled water and packed into a 1n6 cmi20 cm column in Tris-saline buffer, pH 7n5, containing 12n1 g\l Trizma base (Sigma) and 23n4 g\l NaCl. Pooled immunoglobulin fractions obtained by Protein A affinity chromatography were diluted in 5 ml of Tris-saline buffer and passed over the column at flow rate of 0n1 ml\min. The column was then washed with the same buffer and the flow-through fraction containing the unadsorbed antibodies was recovered. Elution of specific anti-CVB4 antibodies was performed at a flow rate of 1 ml\min with elution buffer at pH 3n0. The fractions were pooled, concentrated and neutralized as described above. IgG concentrations in each fraction were estimated using an assumed extinction coefficient of 1n43 for a 1 mg\ml solution at 280 nm.
Plaque neutralization assay.
To assess the presence of anti-CVB4 neutralizing antibodies in plasma and affinity-chromatography fractions, twofold serial dilutions of each fraction in MEM supplemented with 2 % FCS and 1 % -glutamine were incubated with 100 p.f.u. of CVB4 in 96-well microtitre plates for 2 h at 37 mC. Hep-2 cells in suspension were then added at approximately 1i10% cells per well and the plates were re-incubated for 3 days at 37 mC in a humidified incubator with 5 % CO # . Results were expressed as the inverse final dilution (titre) of sample that totally inhibited the viral cytopathic effect.
Immune complexes detection by complement fixation test.
Plasma or plasma fractions were serially diluted twofold in calciummagnesium-Veronal buffer at pH 7n2 (bioMe! rieux) and incubated with 10( p.f.u.\ml CVB4 for 1 h at 37 mC. Fifty µl of CVB4-antibody mixture and 25 µl of guinea pig complement at 1\48 (Dade Behring) were dispensed into a microtitration plate and incubated at 4 mC overnight. The indicator system consisted of 25 µl of antibody-coated red cells added to wells and incubated at 37 mC for 10-30 min. The indicator system was prepared by incubating 50 % sheep red cells (bioMe! rieux) with rabbit anti-sheep haemolysin at 1\1600 (bioMe! rieux) for 30 min at 37 mC. Sedimented red cells forming a button indicate a positive reaction.
Immune complexes quantification. A Quidel Circulating Immune Complex (CIC) C1q EIA kit (Ingen, Rungis, France) was used, according to the manufacturer's instructions, for quantitative detection of specific immune complexes (IC) formed in vitro by incubating either plasma or plasma fractions obtained by CVB4 affinity chromatography, with 10( p.f.u.\ml CVB4 for 1 h at 37 mC. The concentration of IC present in the test specimen was determined by reference to a standard curve. Results were expressed as µg of heat-aggregated human gamma globulin equivalents per ml (µg Eq\ml). Values greater than 4 µg Eq\ml were considered positive for significant levels of IC. C1q-coated and control microwells from the kits were used for IC depletion experiments Immunofluorescence (IF). CVB4-infected PBMCs, CVB4\ antibody-infected PBMCs and mock-infected PBMCs were carefully washed in RPMI at 8 h post-infection. The cells were then treated with trypsin-Versene (Eurobio) for 10 min at 37 mC, removed from the wells by pipetting and washed twice before 10& cells were cytocentrifuged onto clean glass slides. The slides were air-dried and fixed in a solution of 4 % paraformaldehyde (PFA ; Sigma) for 20 min at 4 mC. The slides were washed twice in PBS and permeabilized with cold acetone-methanol (1 : 2, v\v) for 10 min at 20 mC. After washing twice in PBS, the slides were incubated with 5 % normal rabbit serum for 1 h at room temperature in a humidified chamber, washed twice in PBS, and incubated for 1 h at room temperature with monoclonal antibodies to human IFN-α (LT27 : 273 and LT27 : 293) at 1 µg\spot. After three washes in PBS, the slides were stained with a 1 : 100 dilution of FITC-conjugated anti-mouse IgG antibodies (Sigma), counterstained with Evans blue (Sigma), and washed three times in PBS. The slides were then mounted with Permafluor (Coulter), and positive cells were counted in a fluorescence microscope (Leitz Diaplan).
RNA extraction. Native RNA was extracted from cells at 8 h postinfection by the acid guanidinium thiocyanate-phenol-chloroform extraction procedure using a commercial system (RNAgents Total RNA Isolation System ; Promega). Extracted RNA was then dissolved in 50 µl of DEPC-treated water (Sigma) and used in the RT-PCR assays.
Oligonucleotide primers. Human IFN-α1 primers were purchased from Clontech : upstream primer, 5h TGATGGCAACCAGTTCCAG-AAGGCTCAAG-3h ; downstream primer, 5h ACAACCTCCCAGGCA-CAAGGGCTGTATTT 3h. The amplified PCR fragment size is 303 bp. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were synthesized by Eurogentec (Seraing, Belgium) : upstream primer, 5h GTCTTCACCACCATGGAGA 3h ; downstream primer, 5h CCAAAG-TTGTCATGGATGACC 3h. The amplified PCR fragment size is 206 bp.
One step RT-PCR for IFN-α RNA detection. cDNA synthesis and cDNA amplification were performed in a single tube using the Enhanced Avian RT-PCR Kit (Sigma) according to the manufacturer's instructions. The procedure has been described in a previous report from us (Chehadeh et al., 2000 b) . One step RT-PCR was performed in a total volume of 50 µl using 1 µM of each primer and 0n1 µg of extracted RNA and the reaction was carried out using a Perkin Elmer Applied GeneAmp PCR System 2400.
For each RNA sample, GAPDH mRNA was retrotranscribed in cDNA, amplified by RT-PCR and used as a positive control to demonstrate the absence of RT-PCR inhibitors. A negative control (no RNA) was also included in each PCR. The absence of introns within IFN-α genes precludes the distinction between amplification products resulting from reverse-transcribed IFN-α1 mRNA and those arising from residual genomic DNA. Therefore, the absence of contaminating genomic DNA was verified for each RNA sample by carrying out the RT-PCR reaction without adding the reverse transcriptase. Only samples without contaminating genomic DNA have been considered.
Detection of PCR products. The amplified RT-PCR products were analysed on 2 % agarose gel containing 0n5 µg\ml ethidium bromide (Sigma) and visualized using the Gel Doc 2000 system (BioRad). Image processing and analysis operations of DNA bands were performed using Quantity One software (Bio-Rad). A 100 bp DNA Ladder (Gibco BRL) was used as a molecular mass marker. The relative quantity of RT-PCR IFN-α and GAPDH products were compared by serial end-point dilution. The results were expressed as the absorbance ratio of IFN-α and GAPDH amplicons.
Antibody-dependent assays. PBMCs or monocytes were distributed into 96-well tissue culture plates as described above. Virus-W. Chehadeh and others W. Chehadeh and others antibody complexes were made by incubation of plasma fractions at various dilutions with CVB4 for 1 h at 37 mC. CVB4 or CVB4-antibody complexes were added to cells at an m.o.i. of 1 before incubation for 2 h at 37 mC. The cells were then washed three times and cultured in RPMI 1640 containing 10 % FCS (48 h at 37 mC, 5 % CO # atmosphere. After incubation, culture supernatants were harvested, cleared and stored until assayed for the presence of IFN-α. 
Antibodies

Results
Plasma enhances CVB4-induced synthesis of IFN-α
In preliminary experiments, high levels of CVB4-induced IFN-α were produced by PBMCs when virus was preincubated with plasma of healthy subjects at different dilutions (1 : 10" to 1:10%) for 1 h and then added to PBMC cultures. The optimal dilution of plasma differed between subjects and ranged from 1:10# to 1 : 10$ (data not shown). The mean levels of CVB4-induced IFN-α in culture supernatants of PBMCs incubated with plasma at a dilution of 1 : 10# were significantly higher than those in absence of plasma (CVB4 : 135p80 IU\ml vs 3p3 IU\ml, P 0n0001, n l 20) (Fig. 1 a) . FITC staining of IFN-α in CVB4-stimulated PBMCs showed no IFN-α-positive cells, whereas in (CVB4jplasma)-stimulated cells, 5p1% of cells were IFN-α-positive at 8 h post-infection. However, IFN-α mRNA was detected by RT-PCR in extracts of CVB4-and (CVB4jplasma)-stimulated PBMC cultures at 8 h postinfection, but the absorbance ratio for IFN-α amplicons and GAPDH amplicons obtained from (CVB4jplasma)-stimulated PBMC cultures was much higher than that from CVB4-stimulated PBMC cultures (9p3 vs 0n3p0n1). In contrast, IFN-α mRNA was not detected in extracts of control PBMCs (data not shown).
IgG isolated from plasma enhance CVB4-induced synthesis of IFN-α
Plasma samples from five healthy subjects were passed over a Protein A-Sepharose CL-4B column. The resulting eluted fractions containing the IgG antibodies (IgG1, IgG2 and IgG4) and the flow-through fractions (IgG1, -2, -4-free plasma) were preincubated with CVB4 for 1 h at 37 mC before being added to PBMC cultures. High levels of IFN-α were obtained in the presence of eluted fractions (20 µg\ml IgG), whereas no IFN-α production was detected in the presence of flow-through fractions (Fig. 1 b) .
The enhancing effect of eluted fractions on CVB4-induced IFN-α production in PBMC cultures was suppressed significantly when PBMCs were preincubated with 2 µg\ml of either anti-human FcγRII IgG2a antibodies or anti-human FcγRIII IgG1 antibodies but not with anti-human FcγRI IgG1 antibodies (Fig. 2 a) . Irrelevant control antibodies did not inhibit the IgG-mediated enhancement of CVB4-induced IFN-α production. When PBMCs were preincubated with anti-FcγRI, anti-FcγRII or anti-FcγRIII antibodies before adding SV or HSV1, the levels of IFN-α were not reduced (data not shown).
IgG fractions isolated from healthy subjects with anti-CVB neutralizing antibodies had an enhancing activity on CVB4-induced IFN-α production at high dilutions (1 : 10#-1:10$) but not at lower dilutions (1 : 2-1 : 10). On the contrary, human plasma obtained from six children (age range 6-12 months), which did not contain anti-CVB neutralizing antibodies directed against the six serotypes of CVB (CVB1-6), showed no enhancing activity on synthesis of IFN-α (Fig. 2 b) . The role of specific anti-CVB IgG antibodies in IFN-α induction was also suggested when no IFN-α production could be detected in supernatants of PBMC cultures stimulated with CVB4 that were preincubated with irrelevant human IgG at different concentrations (data not shown).
Antibodies without neutralizing activity bind CVB4 and enhance CVB4-induced IFN-α production
To isolate specific anti-CVB IgG antibodies from plasma of healthy subjects, IgG eluted fractions obtained by Protein A affinity chromatography were passed over a DVS-activated Sepharose CL-4B column coupled to CVB4. Adsorbed IgG antibodies were eluted at pH 3n0. From a typical preparation, IgG concentrations in the flow-through and eluted fractions were 6 and 0n08 mg respectively. By using a plaque neutralization assay, we detected high titres of anti-CVB4 neutralizing antibodies in eluted fractions but not in flowthrough fractions (Fig. 3 a) . However, by using the complement fixation test (CFT), CVB4-antibody complexes were detected, as a result of the binding of complement, when CVB4 was preincubated with flow-through or eluted fractions (Fig. 3 b) . CVB4-IgG complexes were also able to bind to C1q coated onto microwells, allowing quantification of IC (Fig. 3 b) . The IC concentrations were IgG-dose dependent (data not shown).
Preincubation of CVB4 with eluted fractions containing anti-CVB4 neutralizing antibodies at different concentrations before adding to PBMC cultures resulted in no detection of IFN-α production, whereas high levels of IFN-α production by PBMCs were detected when CVB4 was preincubated with flow-through fractions at 20 µg\ml (Table 1) . IFN-α concentrations were higher than those obtained when CVB4 was preincubated with IgG obtained from plasma by using Protein A chromatography at the same IgG concentration (20 µg\ml). Next, CVB4\enhancing IgG mixtures were put into C1q-coated microwells to remove immune complexes (IC) before being added to PBMCs. The IC concentrations in CVB4\IgG mixtures after incubation in control or C1q-coated microwells were 37p5 µg Eq\ml and 2p1 µg Eq\ml respectively (n l 5). The IC depletion resulted in a decrease of IFN-α levels in PBMC cultures from 166p65 IU\ml to 23p12 IU\ml (n l 5) (data not shown).
CAR plays a role in antibody-mediated enhancement of CVB4-induced IFN-α production
To examine the effect of CAR on the efficiency of IgGmediated IFN-α production, PBMCs were preincubated for 1 h with anti-human CAR antibodies before challenging with CVB4-IgG complexes. As shown in Fig. 4 , IFN-α production was significantly decreased in the presence of anti-CAR antibodies, whereas control antibodies did not inhibit the IgGmediated enhancement of CVB4-induced IFN-α production. When PBMCs were preincubated with anti-CAR antibodies before adding SV or HSV-1, the levels of IFN-α were not reduced (data not shown).
Monocytes are involved in antibody-mediated enhancement of CVB4-induced IFN-α production
To identify which cells were responsible for IgG enhancement of CVB4-induced IFN-α production, a monocyteenriched PBMC population was segregated from a monocytedepleted PBMC population as described in Methods. CVB4 preincubated with enhancing antibodies induced high levels of IFN-α production in monocyte-enriched cultures, whereas no IFN-α production was detected in monocyte-depleted cultures (Fig. 5 a) . A similar pattern of results was obtained with SV. In contrast, with HSV-1, IFN-α levels were low in supernatants of monocyte-enriched cultures and high in supernatants of monocyte-depleted cultures. Then, CD14 + and CD14 − cells were selected from PBMCs by using immunomagnetic beads before being stimulated with CVB4 preincubated with enhancing IgG. High IFN-α levels were detected in CD14 + cell cultures, whereas IFN-α was not detected in CD14 − cell cultures (Fig. 5 b) . Monocyte-enriched cultures and monocytedepleted cultures were stained for IFN-α in an IF test. When monocyte-enriched cultures were infected with CVB4, the proportion of IFN-α-positive cells was 0n1 %. Preincubation of CVB4 with enhancing IgG (20 µg\ml IgG) increased the proportion of IFN-α-positive cells to 10 %. In contrast, there were no IFN-α-positive cells when monocyte-depleted cultures were infected with CVB4 preincubated in the absence or presence of antibodies (Fig. 5 c) .
Discussion
The current study demonstrates that in the presence of plasma, CVB4 can strongly induce the synthesis of IFN-α, as demonstrated by high levels of mRNA and IFN-α protein. IFN-BJAE CVB4-antibody complexes induce IFN-α production CVB4-antibody complexes induce IFN-α production α mRNA was detected in extracts of CVB-and (CVBkIgG)-stimulated PBMCs, whereas IFN-α protein was detected only in (CVBkIgG)-infected cells ; in contrast, in mock-infected cells, IFN-α mRNA and immunoreactive IFN-α were not detected. IFN-α may be released and consumed locally at the site where the reaction occurred, which may explain, under the limits of our assay, the negative or low level of IFN-α in the supernatant of CVB4-treated PBMCs.
IgG contained in plasma was responsible for the enhancement of CVB4-induced synthesis of IFN-α as demonstrated by the role of an eluted fraction containing IgG obtained from plasma passed over a Protein A-Sepharose column. It can be assumed that IgG played a role in the form of immune complexes with CVB4 for the following reasons. (1) The enhancing effect of virus\eluted fraction mixtures was suppressed by anti-FcγRII and FcγRIII antibodies, which bind IgG effectively only in the form of immune complexes, but not by anti-FcγRI antibodies, which bind Fcγ monovalently with high affinity (Gessner et al., 1998) . (2) Immune complexes formed between enhancing IgG antibodies and CVB4 were able to bind complement and protect sheep red cells from lysis. The adsorption of immune complexes on C1q-coated microwell plates, blocked the enhancing activity of IgG, provided further evidence of the role of specific immune complexes in the enhancement process. (3) IgG fractions isolated from subjects with anti-CVB4 antibodies, but not those obtained from individuals without anti-CVB4 antibodies, enhanced CVB4-induced IFN-α synthesis. Insofar as the Protein ASepharose CL-4B column used to isolate the IgG fraction from human plasma binds only IgG1, IgG2 and IgG4, and that FcγRII and FcγRIII bind IgG1 and IgG3 in the form of immune complexes (Gessner et al., 1998) , it can be suggested that virion-IgG1 complexes were involved in the enhancement process.
Neutralizing anti-CVB4 antibodies were contained in eluted fractions, whereas enhancing antibodies were recovered in flow-through fractions of affinity chromatography with DVSactivated Sepharose CL-4B coupled to CVB4. We cannot exclude the possibility that enhancing antibodies were not detected in the eluted fraction because of the presence of high levels of neutralizing antibodies. However, these results suggest that IgG involved in the enhancement of CVB4-induced IFN-α synthesis and in the neutralization of CVB4 may be different ; otherwise, both types of antibodies would have been recovered in the eluted fraction. The attachment of CVB4 to activated Sepharose may result in conformational changes in the virus structure which prevented binding of enhancing antibodies. It can be explained by previous reports suggesting that portions of enterovirus capsid proteins can be reversibly exposed to the surface (Roivainen et al., 1993) . Together, our data suggest that neutralizing and enhancing antibodies recognize different epitopes at the virus surface. Natural infections of humans by a CVB serotype can induce production of both serotype-and CVB group-specific antibodies (Pattison, 1983 ; Frisk et al., 1989) , which can explain the fact that eluted anti-CVB4 neutralizing antibodies could also neutralize, to a lesser degree, CVB3 (data not shown). We cannot exclude the possibility that the enhancing activity seen in the flow-through fraction is due to the presence of anti-CVB enhancing antibodies which cross-react with different CVB serotypes. This is in line with studies showing that specific enhancing antisera to purified haemagglutinin or neuraminidase of influenza A viruses cross-react with different influenza A subtypes (Tamura et al., 1991) . Further investigations are needed to explore these hypotheses.
The presence of both low-affinity FcγR and CAR molecules on the target cells was required for IgG-dependent enhancement of CVB4-induced IFN-α synthesis ; otherwise, blocking of FcγR or CAR independently could not inhibit IFN-α synthesis. It has been reported that FcγRIII colocalizes with decayaccelerating factor (DAF, CD55), which is a receptor for CVB3 (Bhatia et al., 1998) . Whether FcγRII, FcγRIII and CAR colocalize at the surface of IFN-α-producing cells remains to be determined. The strong reduction of IFN-α levels in culture obtained by preincubating PBMCs with anti-FcγRII or antiFcγRIII antibodies or anti-CAR antibodies in IgG-enhanced IFN-α synthesis suggests a role for interactions between CVB4-IgG complexes, FcγR and CAR which result in induction of IFN-α. It cannot be ruled out that CVB4-IgG complexes act as cross-linking agents on FcγRII, FcγRIII and CAR altogether to trigger a combined signal for IFN-α. Further studies are needed to clarify whether these proteins act together at the same time or sequentially. Our results are similar to those reported recently by Palmer et al. (2000) showing that FcγRII plays a role in the induction of IFN-α in PBMCs by poliovirus-antibody complexes (Palmer et al., 2000) . However, there are some differences with the present study since in their experiments FcγRIII did not play a role. These differences could be related either to the techniques and\or to the virus used.
Production of IFN-α by monocytes and dendritic cell precursors in response to in vitro stimulation with SV and HSV-1 has been well characterized (Saksela et al., 1984 ; Gobl et al., 1988 ; Siegal et al., 1999) . Therefore, the pattern of results obtained with CVB4 compared with SV and HSV-1 in our experiments, together with the detection of IFN-α-positive cells by IF staining in monocyte-enriched cultures and not in monocyte-depleted cultures and the production of IFN-α by CD14 + cells, suggest that the major interferon-producing cells in response to CVB4-IgG complexes were CD14 + monocytes.
The mechanism of CVB4\IgG-induced IFN-α synthesis in PBMCs is unknown. It has been suggested that the induction of IFN-α by poliovirus-antibody complexes depends on CD32-mediated phagocytosis of RNA-containing particles (Palmer et al., 2000) . Further investigations are needed to determine whether the synthesis of IFN-α in our experiments reflects an enhanced entry of CVB genome into monocytes through an antibody-dependent mechanism.
These data show that antibodies devoid of neutralizing activity can play a role in the interaction between CVB and PBMC by enhancing the synthesis of IFN-α, which may increase the innate antiviral defence of the host against CVB. Whether such an effect of antibodies also operates in vivo is still unclear. Studies are in progress in our laboratory to investigate whether antibodies can be involved in the previously reported production of IFN-α in individuals with CVB RNA in their peripheral blood .
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